Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

(2018) Linda M. Liau et al.   Journal of Translational Medicine

Recurrent Glioblastoma Treated with Recombinant Poliovirus

(2018) Annick Desjardins et al.   NEW ENGLAND JOURNAL OF MEDICINE

Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma

(2018) Martin J. B. Taphoorn et al.   JAMA Oncology

AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields)

(2018) Anna Shteingauz et al.   Cell Death & Disease

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

(2017) Roger Stupp et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014

(2017) Quinn T Ostrom et al.   NEURO-ONCOLOGY

Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells

(2017) Moshe Giladi et al.   Radiation Oncology

Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines

(2017) Narasimha Kumar Karanam et al.   Cell Death & Disease

Biological activity of tumor-treating fields in preclinical glioma models

(2017) Manuela Silginer et al.   Cell Death & Disease

Tumor treating fields: a novel treatment modality and its use in brain tumors

(2016) Andreas F. Hottinger et al.   NEURO-ONCOLOGY

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma

(2015) Roger Stupp et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Tumor Treating Fields Perturb the Localization of Septins and Cause Aberrant Mitotic Exit

(2015) Nidhi Gera et al.   PLoS One

Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells

(2015) Moshe Giladi et al.   Scientific Reports

Improving Adherence to Oral Cancer Therapy in Clinical Practice

(2014) Debbie A. McCue et al.   PHARMACOTHERAPY

Characterization and Management of Dermatologic Adverse Events With the NovoTTF-100A System, a Novel Anti-mitotic Electric Field Device for the Treatment of Recurrent Glioblastoma

(2014) Mario E. Lacouture et al.   SEMINARS IN ONCOLOGY

Post Hoc Analyses of Intention-to-Treat Population in Phase III Comparison of NovoTTF-100A™ System Versus Best Physician’s Choice Chemotherapy

(2014) Andrew A. Kanner et al.   SEMINARS IN ONCOLOGY

Alternating Electric Fields (Tumor-Treating Fields Therapy) Can Improve Chemotherapy Treatment Efficacy in Non-Small Cell Lung Cancer Both In Vitro and In Vivo

(2014) Moshe Giladi et al.   SEMINARS IN ONCOLOGY

Response Patterns of Recurrent Glioblastomas Treated With Tumor-Treating Fields

(2014) Josef Vymazal et al.   SEMINARS IN ONCOLOGY

NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

(2012) Roger Stupp et al.   EUROPEAN JOURNAL OF CANCER

Improved survival time trends for glioblastoma using the SEER 17 population-based registries

(2011) Matthew Koshy et al.   JOURNAL OF NEURO-ONCOLOGY